Benzodiazepine and Unhealthy Alcohol Use Among Adult Outpatients by Hirschtritt, Matthew E. et al.
Benzodiazepine and Unhealthy Alcohol Use Among Adult 
Outpatients
Matthew E. Hirschtritt, MD, MPH,
Department of Psychiatry and the UCSF Weill Institute for Neurosciences, University of 
California, San Francisco (MEH), San Francisco, CA;
Vanessa A. Palzes, MPH,
The Permanente Medical Group, Department of Psychiatry (MEH), Oakland, CA;
Andrea H. Kline-Simon, MS,
Division of Research, Kaiser Permanente of Northern California (MEH, VAP, AHK-S, CIC, SAS), 
Oakland, CA;
Kurt Kroenke, MD,
Indiana University School of Medicine (KK), Indianapolis, IN;
Cynthia I. Campbell, PhD, MPH,
Regenstrief Institute, Inc (KK), Indianapolis, IN;
Stacy A. Sterling, DrPH, MSW
VA Health Services Research and Development, Center for Health Information and 
Communication (KK), Indianapolis, IN.
Abstract
OBJECTIVES: Concomitant excessive alcohol consumption and benzodiazepine use is 
associated with adverse health outcomes. We examined associations of unhealthy alcohol use and 
other patient characteristics with benzodiazepine use.
STUDY DESIGN: A cross-sectional analysis of 2,089,525 Kaiser Permanente of Northern 
California outpatients screened for unhealthy alcohol use in primary care between November 1, 
2014, and December 31, 2016.
METHODS: We fit multivariable generalized linear models to estimate the associations between 
unhealthy alcohol use and benzodiazepine dispensation and, among patients who were dispensed a 
benzodiazepine, mean doses (in mean lorazepam-equivalent daily doses [LEDDs]) and 
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prescription durations. We controlled for patient sex, age, race/ethnicity, estimated household 
income, Charlson Comorbidity Index (CCI) score, anxiety disorder, alcohol use disorder, 
insomnia, musculoskeletal pain, and epilepsy.
RESULTS: In the 12 months centered around (6 months before and 6 months after) the first 
alcohol-screening visit, 7.5% of patients used benzodiazepines. The following characteristics were 
independently associated with higher rates of benzodiazepine use, higher LEDD, and longer 
prescription duration: older age, white race/ethnicity, lower estimated household income, higher 
CCI score, and the presence of an anxiety disorder, insomnia, musculoskeletal pain, or epilepsy. 
Women and patients with an alcohol use disorder or unhealthy alcohol use, compared with men 
and patients with low-risk drinking or abstinence, were more likely to use a benzodiazepine; 
however, their LEDDs were lower and their prescription durations were shorter.
CONCLUSIONS: Benzodiazepine use in primary care was associated with older age, female sex, 
white race/ethnicity, lower socioeconomic status, and unhealthy alcohol use. These findings may 
be applied to develop policies and interventions to promote judicious benzodiazepine use.
Benzodiazepines have been increasingly used in the United States, leading to increases in 
overdose mortality and healthcare utilization due to their potent sedative properties. Between 
1996 and 2013, the percentage of US adults who filled a benzodiazepine prescription 
increased from 4.1% to 5.6%, and overdose mortality involving benzodiazepines increased 
from 0.58 to 3.07 per 100,000 adults.1 In a large primary care sample, 15% of patients were 
prescribed a benzodiazepine, one-third of whom received high-dose benzodiazepines (ie, a 
daily dose equivalent of ≥30 mg/day of diazepam); high-dose recipients were more likely 
than low-dose recipients to have multiple medical comorbidities and high healthcare 
utilization.2 Furthermore, between 2003 and 2015, the percentage of outpatient medical 
visits including a benzodiazepine prescription doubled, and more than half of these visits 
were to primary care physicians.3
Between 7.5% and 20% of primary care patients acknowledge unhealthy alcohol use,4,5 
defined as use exceeding recommended weekly or daily limits.6 Excessive alcohol use is 
associated with numerous individual and societal consequences, such as development or 
exacerbation of medical and mental health comorbidities, decreased medication adherence, 
increased HIV risk behaviors, motor vehicle crashes, and interpersonal violence.7 Unhealthy 
alcohol use may precede development of an alcohol use disorder8 and frequently goes 
undetected in routine clinical care.9,10 In this context, the US Preventive Services Task Force 
recommends screening all adult primary care patients for unhealthy alcohol use and offering 
patients with unhealthy alcohol use brief behavioral counseling.11
When benzodiazepines and alcohol are used concurrently, their sedative effects significantly 
increase the risk of adverse events, including fatal overdose.12 In 2010, alcohol was involved 
in 27.2% of benzodiazepine-related visits and 21.4% of benzodiazepine-related deaths in US 
emergency departments.13 Long-term consequences of combined benzodiazepine and 
alcohol use include cardiovascular, gastrointestinal, hepatic, kidney, and neurologic injury 
and exacerbation of psychiatric conditions.14,15
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Nationally representative survey data from 2015–2016 suggest that past-year alcohol use or 
an alcohol use disorder is associated with an increased risk of concurrent benzodiazepine 
use, misuse, and use disorder.16,17 Similarly, among Medicare beneficiaries in 2002, 
presence of drug or alcohol use or dependence was associated with higher odds of 
benzodiazepine use.18 However, to our knowledge, no health system, primary care–based 
studies have examined patient characteristics associated with benzodiazepine dispensation, 
mean dose, and prescription duration. This information may inform the development of 
tailored interventions to reduce exposure to benzodiazepines among patients with unhealthy 
alcohol use.
In this study, we examined the prevalence of benzodiazepine use and its associations with 
patient demographic and clinical characteristics, including unhealthy alcohol use, among 
Kaiser Permanente of Northern California (KPNC) adult outpatients who were screened for 
alcohol use in primary care clinics. We hypothesized that people drinking at unhealthy 
levels, compared with low-risk drinkers and abstainers, would be less likely to receive 
benzodiazepines and would receive prescriptions of lower doses and shorter durations. 
Although this contrasts with previous national trends, we postulated that the combination of 
recent warnings about rising benzodiazepine use in the United States, concerns about 
concurrent use with other substances, and a primary care initiative in our healthcare system 
to detect and reduce unhealthy alcohol use would sensitize clinicians to reconsider 
benzodiazepine prescribing in this patient subgroup.
METHODS
Design, Setting, and Participants
We conducted a retrospective, cross-sectional study using electronic health record (EHR)–
derived data among adult outpatients screened for alcohol use in KPNC primary care clinics. 
KPNC is an integrated healthcare delivery system with more than 4 million members that 
covers approximately 30% of the population in the served geographic areas. For these 
analyses, we identified KPNC members 18 years or older who were screened for unhealthy 
alcohol use with 1 or more completed alcohol screenings as part of an ongoing primary 
care–based alcohol screening and brief intervention protocol (Alcohol as a Vital Sign 
[AVS])19 between November 1, 2014, and December 31, 2016. We defined the study period 
as the 12-month period centered around (6 months before and 6 months after) each patient’s 
clinic visit in which the first AVS screening occurred. We excluded patients with 
noncontinuous KPNC coverage during the study period (eAppendix Methods [eAppendix 
available at ajmc.com]). Use of these data was approved by the institutional review boards of 
KPNC and the University of California, San Francisco.
Outcome: Benzodiazepine Use
We included outpatient dispensations for benzodiazepines filled at KPNC pharmacies in the 
12 months centered around a patient’s first AVS screening visit in a primary care clinic. We 
extracted data for oral formulations of all benzodiazepine-containing medications (ie, 
alprazolam, chlordiazepoxide, clobazam, clonazepam, clorazepate, diazepam, estazolam, 
flurazepam, lorazepam, midazolam, oxazepam, temazepam, and triazolam) dispensed during 
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the study period. For each patient, we assessed the following prescription attributes: (1) 
whether a benzodiazepine had been dispensed; (2) the duration of the benzodiazepine 
prescriptions (calculated by summing the total number of days supplied in the study 
period20); and (3) the mean daily benzodiazepine dose, expressed in mean lorazepam-
equivalent daily dose (LEDD), which is an average over the 12-month study period 
(eAppendix Methods and eAppendix Table 1).
Covariates
Patient sex, age, and race/ethnicity (Asian, black/African American, Hispanic, white, and 
other/unknown) were extracted from the EHR at the time of the first AVS screening. We 
estimated household income from the United States Census 2010 median household income 
data by geocoding patients’ residential addresses to Census blocks.21,22 Using International 
Classification of Diseases, Ninth Edition and International Classification of Diseases, Tenth 
Edition, Clinical Modification codes, we assessed for the presence of the following 
encounter-associated codes in the study period: anxiety disorders, insomnia, musculoskeletal 
pain, alcohol use disorders (including alcohol-related psychoses, dependence, and abuse; 
excluding conditions in remission), and epilepsy (eAppendix Table 2). In addition, we 
estimated patients’ medical comorbidity burden using the Charlson Comorbidity Index 
score, which estimates 1-year mortality risk based on a weighted score of 17 conditions.
23–25
To determine whether a patient engaged in unhealthy alcohol use, we used EHR-
documented alcohol screening data collected as part of the AVS protocol during the study 
period. During the primary care visit “rooming” process, medical assistants asked all 
patients to estimate within the past 90 days (1) the mean number of days per week they 
consumed alcohol and (2) how many alcoholic drinks they consumed “on a typical drinking 
day.” Using these variables, the EHR calculates the mean number of alcoholic drinks 
consumed weekly (ie, mean number of drinking days per week multiplied by the number of 
drinks consumed on a typical drinking day).26 Based on guidelines established by the 
National Institute on Alcohol Abuse and Alcoholism,6 we defined drinking severity as “low-
risk alcohol use” (0–14 drinks per week for men ≤65 years or 0–7 drinks per week for all 
women and for men >65 years) or “unhealthy alcohol use” (>14 drinks per week for men 
≤65 years or >7 drinks per week for all women and for men >65 years).
Analytic Approach
We applied χ2 and Wilcoxon rank-sum tests to examine differences in categorical and 
continuous patient demographic and clinical characteristic variables (including presence of 
unhealthy alcohol use) by whether the patient filled a prescription for a benzodiazepine in 
the 12 months centered around their first AVS screening visit. We fit multivariable logistic 
regression models to estimate the adjusted odds ratios (AORs) and corresponding 95% CIs 
of being dispensed a benzodiazepine by patient characteristics. Among patients who were 
dispensed a benzodiazepine during the study period, we fit log-linear and negative binomial 
regression models (accounting for positive skew and overdispersion of the data) to estimate 
the adjusted rate ratios (ARRs) of mean LEDD and duration of their prescriptions, 
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respectively, by patient characteristics. All analyses were performed using SAS version 9.4 
(SAS Institute Inc; Cary, North Carolina). Significance was assessed at 2-sided P <.05.
RESULTS
Cohort Characteristics
Approximately 87% of eligible KPNC members during the defined study period completed 
1 or more AVS screenings, and 70% of the benzodiazepine prescriptions were ordered by a 
primary care provider (ie, internal, family, preventive, or adolescent medicine or pediatrics). 
Among KPNC members included in these analyses, approximately 97% had a continuous 
prescription benefit for KPNC pharmacies during the 12-month study period. The analytic 
cohort consisted of 2,089,525 patients (median [interquartile range] age = 49.0 [29.0] years; 
53.7% female; 50.0% white; 4.0% unhealthy alcohol users) after excluding patients without 
continuous KPNC coverage in the 12 months centered around the first AVS screening (n = 
803,991) and patients with missing Census-derived estimated household income data (n = 
1390) (Table 1).
Benzodiazepine Use
In the study period, 157,449 patients (7.5% of the study sample) filled a prescription for a 
benzodiazepine (Table 1). Patients with unhealthy alcohol use had slightly higher odds of 
using benzodiazepines compared with patients with low-risk alcohol use (AOR, 1.15; 95% 
CI, 1.12–1.19) (Table 2). From the same multivariable analysis, women had 64% higher 
odds of using a benzodiazepine compared with men (AOR, 1.64; 95% CI, 1.62–1.66). 
Conversely, nonwhite patients had significantly lower odds of using benzodiazepines 
compared with white patients. Among racial/ethnic groups, Asian patients were the least 
likely to use benzodiazepines, with an AOR of 0.38 (95% CI, 0.37–0.38), representing 62% 
lower odds of using benzodiazepines compared with white patients. Older patients had 
significantly higher odds of using benzodiazepines compared with younger patients aged 18 
to 39 years, with AORs of 1.82 (95% CI, 1.79–1.84) and 1.77 (95% CI, 1.73–1.80) for 
patients aged 40 to 65 and older than 65 years, respectively. Anxiety disorders, insomnia, 
musculoskeletal pain, epilepsy, and alcohol use disorder were all significantly associated 
with benzodiazepine use.
Mean Daily Dose and Duration of Benzodiazepine Prescriptions
Among patients with benzodiazepine prescriptions during the study period, the mean (SD) 
LEDD was 0.58 (1.51) mg/day and mean (SD) duration was 87.9 (114.0) days. Patients with 
unhealthy alcohol use had 40% lower LEDDs (ARR, 0.60; 95% CI, 0.55–0.66) and 18% 
shorter durations (ARR, 0.82; 95% CI, 0.80–0.84) compared with patients with safe alcohol 
use (Table 3). Women had ARRs of 0.85 (95% CI, 0.83–0.87) and 0.92 (95% CI, 0.90–0.93), 
representing a 15% lower LEDD and an 8% shorter duration of benzodiazepine 
prescriptions, respectively, compared with men. Asian patients had the lowest LEDD and 
shortest prescription durations of any racial/ethnic group compared with white patients. 
Whereas LEDD was highest among patients aged 40 to 65 years compared with patients 
aged 18 to 39 years (ARR, 1.49; 95% CI, 1.43–1.55), prescription durations were the longest 
among patients 65 years or older compared with patients aged 18 to 39 years (ARR, 2.04; 
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95% CI, 2.00–2.08). Higher LEDD and longer prescription durations were also significantly 
associated with low (compared with high) Census-derived estimated household income and 
the presence of an anxiety disorder, insomnia, musculoskeletal pain, and epilepsy.
DISCUSSION
This study is the first to our knowledge to examine the association of unhealthy alcohol use 
with benzodiazepine use, dosage, and prescription duration in a large primary care sample. 
Notably, 7.5% of patients in this cohort were dispensed a benzodiazepine in a 12-month 
period.1,27 In addition, women, older adults, and white patients were more likely to use 
benzodiazepines.
The rate of unhealthy alcohol use of 4.0% in our sample is lower than estimates from other 
health maintenance organization–based primary care samples (7.5%−20%)4,5 but is within 
the range estimated in population-based survey samples (0.3%−20%).27 This discrepancy 
may be attributable to different populations, years of data collection, and definitions of 
unhealthy alcohol use. Similarly, the prevalence of filled benzodiazepine prescriptions in our 
sample (7.5%) is consistent with a cross-sectional analysis of US retail pharmacies (5.2% of 
adults filled a prescription for a benzodiazepine in 2008)28 and with data from the Medical 
Expenditure Panel Survey (the prevalence of filled benzodiazepine prescriptions between 
1996 and 2013 among noninstitutionalized adults increased from 4.1% to 5.6%).1 However, 
among adults in a primary care practice–based research network in 2011 and 2012, 15% of 
patients were prescribed a benzodiazepine.2 This larger percentage may reflect ordered 
prescriptions instead of filled prescriptions; the number of ordered prescriptions is likely to 
be greater than the corresponding number of filled prescriptions.29
Comparing our results regarding the concomitant use of benzodiazepines and alcohol with 
other samples is challenging given the methodologic heterogeneity among previous studies. 
For instance, among psychiatric outpatients (n = 93), roughly 40% used a benzodiazepine 
and simultaneously consumed alcohol; furthermore, alcohol use severity was associated with 
higher odds of benzodiazepine use (OR, 2.4; 95% CI, 1.3–4.2).30 In a study examining 
nationally representative survey data from 1999 to 2002, Jalbert and colleagues31 found that 
8% to 10% of adult respondents reported both benzodiazepine and unhealthy alcohol use. 
Consistent with our findings, Kroll and colleagues2 examined data from a large primary care 
sample and found that patients with a diagnosis of alcohol abuse (compared with those 
without) had higher odds of benzodiazepine use (OR, 1.5; 95% CI, 1.3–1.7). In the 
emergency department setting, Jones and colleagues32 found that 27.2% of benzodiazepine-
related visits involved alcohol. However, in smaller studies involving older patients33 and 
college students,34 the prevalence of concomitant benzodiazepine and unhealthy alcohol use 
(approximately 3% in these 2 samples) was significantly lower than what we found in this 
sample.
Clearly, previous analyses of concomitant alcohol and benzodiazepine use vary widely in 
their study populations, periods, and definitions of unhealthy alcohol consumption and 
benzodiazepine use. However, in general, the existing literature supports our conclusion that 
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unhealthy alcohol use is associated with a greater likelihood of concomitant benzodiazepine 
use.
Our study adds to the literature by examining not only benzodiazepine use but also mean 
doses and prescription durations among subpopulations of primary care patients. 
Interestingly, we found that although patients with unhealthy alcohol consumption were 
more likely to use benzodiazepines, the benzodiazepines were prescribed to them at lower 
doses and for shorter durations. This pattern persisted even when accounting for the 
presence of an alcohol use disorder, for which benzodiazepines may be prescribed to 
manage alcohol withdrawal. These findings fail to confirm the first part of our hypothesis 
(ie, patients with unhealthy alcohol use are less likely to use benzodiazepines) but do 
confirm the second part of our hypothesis (ie, that these patients would use benzodiazepines 
for shorter periods and at lower doses). One possible explanation for this pattern of findings 
is that those drinking at unhealthy levels may be more likely to use multiple abusable 
substances,34 but that clinicians, aware of the contraindications of concomitant use, limit the 
dose and duration of benzodiazepines for these patients. It is also possible that patients with 
unhealthy alcohol use may voluntarily limit their use of benzodiazepines to avoid functional 
impairment associated with concurrent alcohol and high-dose benzodiazepine consumption.
We also found, similar to results of surveys3,17 and of studies based on Medicare18 and 
commercial insurance claims,28,35 that women were more likely, and nonwhite patients less 
likely, to use benzodiazepines. Furthermore, we found that women and nonwhite patients 
who used benzodiazepines used them at lower doses and for shorter durations compared 
with men and white patients who used benzodiazepines.36,37 Women may be more likely to 
seek treatment for an anxiety disorder.38 Therefore, women may be more likely than men to 
report anxiety relief and to require lower doses of benzodiazepines in part because they are 
simultaneously receiving nonbenzodiazepine treatments (eg, antidepressants, 
psychotherapy).39 Simultaneously, women may use benzodiazepines at lower doses and for 
shorter amounts of time compared with men in part because clinicians may believe sex 
moderates benzodiazepine metabolism, despite limited evidence to support this contention.40 
Previous research demonstrates that nonwhite patients receive fewer benzodiazepine 
prescriptions than white patients; however, white patients were more likely to have a 
benzodiazepine dependence diagnosis.41,42 Nonwhite patients may be less trusting of the 
healthcare system, particularly as it relates to seeking help for mental health problems.43,44 
White patients may be more assertive in requesting symptom relief45 compared with 
nonwhite patients, who may be less likely to seek medical help for psychiatric symptoms 
such as anxiety.46 Furthermore, some Asian patients may be more likely to seek 
nonallopathic remedies for mental health concerns in primary care.47 Symptoms of anxiety 
in nonwhite patients may also be underrecognized or undertreated by clinicians, resulting in 
fewer benzodiazepine prescriptions for nonwhite patients. These sex- and ethnicity-
associated disparities in benzodiazepine prescribing may also be the result of implicit 
clinician biases.48
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These results should be interpreted in the context of several limitations. As with all 
observational studies, causality cannot be determined. Pharmacy data reflect dispensations 
and we are unable to measure patient medication consumption; nonetheless, dispensations 
are commonly used in pharmacoepidemiologic studies49,50 and, in the current sample, 
approximately 84% of prescribed benzodiazepines were filled in KPNC pharmacies. 
Additionally, our results may not be generalizable to uninsured populations. However, some 
of our findings are consistent with other, nationally representative samples (eg, lower 
benzodiazepine use among nonwhite patients41,42), suggesting that other findings in our 
study may also be applicable to the general US primary care adult population.
We are also unable to determine whether benzodiazepine use was inappropriate or 
unhealthy; subsequent studies may identify potentially inappropriate benzodiazepine use 
using algorithms, such as those used in geriatric samples.51 Likewise, by restricting our 
analyses to benzodiazepine use, we did not examine concurrent opioid use, especially among 
patients with chronic pain. Compared with patients who only use opioids, patients who use 
both opioids and benzodiazepines are at higher risk of overdose52; therefore, national 
guidelines recommend against prescribing benzodiazepines with opioids.53 Future studies 
may examine the association among benzodiazepine and opioid use with unhealthy alcohol 
consumption.
We included conditions frequently associated with benzodiazepine prescriptions; however, 
benzodiazepines may be prescribed for other disorders, such as anxious depression.54 
Finally, statistically significant associations may be a product of the large sample size of our 
study; therefore, we have focused our conclusions on associations with larger AORs and 
ARRs, which are most likely to be clinically meaningful and successfully replicated in other 
primary care samples. If these associations are replicated in subsequent studies, they may be 
applied to develop and validate clinical decision support systems, such as a quantitative risk-
stratification tool to identify patients at high risk of concomitant benzodiazepine and 
unhealthy alcohol use.
CONCLUSIONS
In this large primary care cohort, unhealthy drinking was associated with higher rates of 
benzodiazepine use. However, benzodiazepine mean dose was lower and duration of use was 
shorter among patients with unhealthy drinking. Nonetheless, these results suggest that 
concomitant benzodiazepine and excessive alcohol use among primary care patients should 
receive increased vigilance, and health system–wide efforts to reduce this potentially lethal 
combination should be considered.
Source of Funding:
This research was supported by a grant from the National Institute on Alcohol Abuse and Alcoholism (grant 
number R01-AA025902-01).
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1. Further Description of the Alcohol as a Vital Sign Initiative Workflow
Alcohol as a Vital Sign (AVS) is a primary care clinic-based alcohol screening, brief 
intervention and referral to treatment initiative begun in June 2013 and used in all adult 
primary care clinics in Kaiser Permanente Northern California (KPNC).1 During the pre-
visit evaluation, in addition to recording conventional vital signs, medical assistants asked 
patients structured evidence-based screening questions, embedded in the electronic health 
record (EHR), based on the National Institute on Alcohol Abuse and Alcoholism’s (NIAAA) 
guide for clinicians “Helping Patients Who Drink Too Much”2 including: (1) On average, 
how many days a week do you have an alcoholic drink?, and (2) On a typical drinking day, 
how many drinks do you have? For patients who asked what constitutes 1 “drink,” medical 
assistants provided the following examples: 12 ounces of beer or a wine cooler, 5 ounces of 
table wine, 3–4 ounces of fortified wine, 1 “jigger” (1.5 ounces) of brandy, or 1 shot (1.5 
ounces) of 80-proof distilled spirits.2 Medical assistants could enter any whole integer or 
select “refused to respond” or “not applicable” for either question. The initial AVS medical 
assistant trainings were conducted in small groups by nurse managers at each Medical 
Center. Ongoing medical assistant training also occurs at each Medical Center and is 
delivered by nurse managers. The initial curricula and training materials were standardized 
across the Northern California region, and there is an online repository that contains training 
materials and is available to all Kaiser Permanente employees. Thus, training is consistent 
across all medical assistants, and any possible variations in delivery and recording of the 
AVS screening questions are likely to be minimal.
Approximately 87% of all adult, primary care patients completed this screening within the 
current study period. Patients who exceeded NIAAA’s weekly limits (>7 for women and 
men aged >65 years, >14 for men aged ≤65 years)2 were offered time-limited, office-based 
counselling by physicians based on motivational interviewing principles,3 as well as referral 
to chemical dependency treatment, if needed.
2. Calculation of Mean Lorazepam-Equivalent Daily Dose (LEDD)
We calculated each patient’s mean LEDD of benzodiazepines by:
1. converting the strength of individual medications to lorazepam-equivalents in 
milligrams (see eAppendix Table 1, below), and then
2. calculating the total lorazepam-equivalents milligrams of all benzodiazepines 
filled within the 12 months around each patient’s first AVS screening encounter 
in the study period, and then dividing the total number of milligrams by 366.4
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eAppendix Table 1.
Conversion of Individual Benzodiazepines to Lorazepam-Equivalents*















The medications included in this table are limited to the benzodiazepines that were dispensed to patients in the current 
study cohort.
eAppendix Table 2.




300.0*, 300.2*, 300.3, 309.21, 309.24, 309.28, 
309.81, 313.0
F40.***,F41.***,F42.***, F43.0, 
F43.1*, F43.22, F43.23, F43.8, F43.9
Insomnia 307.4*, 327.00, 327.01, 327.02, 327.09, 780.50, 
780.51, 780.52, 780.55, 780.56, 780.59
G47.0*, G47.2*, G47.8, G47.9, F51.0*, 
F51.8, F51.9, Z72.82*
Seizure disorder 345.** G40.***
Musculoskeletal pain back pain (721.3* − 721.9*, 722.2*, 722.30, 
722.70, 722.80, 722.90, 722.32, 722.72, 722.82, 
722.33, 722.73, 722.83, 724.**, 737.1*, 737.3*, 
738.4, 738.5, 739.2, 739.3, 739.4, 756.10, 756.11, 
756.12, 756.13, 756.19, 805.4, 805.8, 839.2*, 
839.42, 846, 846.0, 847.1, 847.3, 847.2, 847.9), 
neck pain (721.0*, 721.1*, 722.0*, 722.31, 
Available upon request in spreadsheet 
format
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722.71, 722.81, 722.91, 723.**, 839.0*, 839.1*, 





291*, 303* (excluding 303.03, 303.93), 305.0* 
(excluding 305.03)
F10.1*, F10.9*, F10.2* (excluding 
F10.11, F10.21), F10.9*
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Among patients in an integrated healthcare delivery system who were screened in 
primary care for unhealthy alcohol use, we examined cross-sectional benzodiazepine use 
patterns.
• Unhealthy alcohol users, patients with an alcohol use disorder, and women 
were more likely to use benzodiazepines, but at lower doses and for shorter 
durations, compared with low-risk alcohol users and men.
• Patients who were older, white, and of lower socioeconomic status were more 
likely to use benzodiazepines and had higher doses and prescription durations.
• These findings may inform the development of systemwide interventions to 
address disproportionate benzodiazepine use among specific patient groups, 
especially among unhealthy alcohol users.
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TABLE 1.









(n = 1,932,076) P
a
Sex, n (%) <.001
 Male 967,348 (46.3) 49,997 (31.8) 917,351 (47.5)
 Female 1,122,177 (53.7) 107,452 (68.2) 1,014,725 (52.5)
Age in years <.001
 18–39, n (%) 694,764 (33.2) 31,699 (20.1) 663,065 (34.3)
 40–65, n (%) 921,929 (44.1) 77,298 (49.1) 844,631 (43.7)
 >65, n (%) 472,832 (22.7) 48,452 (30.8) 424,380 (22.0)
 Median (IQR) 49.0 (29.0) 56.0 (24.0) 49.0 (29.0) <.001
Race/ethnicity,
b
 n (%) <.001
 White 1,044,613 (50.0) 103,941 (66.0) 940,672 (48.7)
 Asian 378,411 (18.1) 1 1,398 (7.2) 367,013 (19.0)
 Black/African American 144,331 (6.9) 9684 (6.2) 134,647 (7.0)
 Hispanic 386,149 (18.5) 22,765 (14.5) 363,384 (18.8)
 Other/unknown 136,021 (6.5) 9661 (6.1) 126,360 (6.5)
Household income, n (%) <.001
 High 696,680 (33.4) 50,630 (32.1) 646,050 (33.4)
 Middle 696,487 (33.3) 53,017 (33.7) 643,470 (33.3)
 Low 696,358 (33.3) 53,802 (34.2) 642,556 (33.3)
CCI score, median (IQR) 0 (0) 0 (1.0) 0 (0) <.001
Anxiety disorder, n (%) <.001
 No 1,913,956 (91.6) 91,205 (57.9) 1,822,751 (94.3)
 Yes 175,569 (8.4) 66,244 (42.1) 109,325 (5.7)
Insomnia, n (%) <.001
 No 2,017,560 (96.6) 133,051 (84.5) 1,884,509 (97.5)
 Yes 71,965 (3.4) 24,398 (15.5) 47,567 (2.5)
Musculoskeletal pain, n (%) <.001
 No 1,205,075 (57.7) 58,267 (37.0) 1,146,808 (59.4)
 Yes 884,450 (42.3) 99,182 (63.0) 785,268 (40.6)
Alcohol-use disorder, n (%) <.001
 No 2,070,71 1 (99.1) 152,583 (96.9) 1,918,128 (99.3)
 Yes 18,814 (0.9) 4866 (3.1) 13,948 (0.7)
Epilepsy, n (%) <.001
 No 2,075,836 (99.3) 154,850 (98.3) 1,920,986 (99.4)
 Yes 13,689 (0.7) 2599 (1.7) 1 1,090 (0.6)
Any associated diagnosis,
c
 n (%) <.001
 No 1,100,896 (52.7) 30,066 (19.1) 1,070,830 (55.4)
 Yes 988,629 (47.3) 127,383 (80.9) 861,246 (44.6)


























 n (%) <.001
 No 2,005,335 (96.0) 149,509 (95.0) 1,855,826 (96.1)
 Yes 84,190 (4.0) 7940 (5.0) 76,250 (3.9)
CCI indicates Charlson Comorbidity Index; IQR, interquartile range.
a
Chi-squared tests were used for categorical variables and Wilcoxon rank-sum tests were used for continuous variables.
b
Race/ethnicity data were self-reported by patients and recoded administratively into predefined categories.
c
Includes presence of diagnostic codes for an anxiety disorder, insomnia, musculoskeletal pain, or an alcohol-use disorder.
d
Patients were asked to estimate alcohol use within the past 90 days. Unhealthy alcohol use was defined as more than 7 drinks per week for all 
women and men older than 65 years or more than 14 drinks per week for men 65 years or younger. See eAppendix Methods for additional 
information.
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TABLE 2.
Associations of Demographic and Clinical Characteristics With Dispensation of a Benzodiazepine




 Female 1.64 (1.62–1.66) <.001
Age in years
 18–39 1
 40–65 1.82 (1.79–1.84) <.001




 Asian 0.38 (0.37–0.38) <.001
 Black/African American 0.65 (0.63–0.66) <.001
 Hispanic 0.61 (0.60–0.62) <.001
 Other/unknown 0.74 (0.72–0.76) <.001
Household income
 High 1
 Middle 1.02 (1.01–1.04) <.001
 Low 1.02 (1.00–1.03) .02
CCI score, mean (SD)
c 1.12 (1.12–1.12) <.001
Anxiety disorder
 No 1
 Yes 9.71 (9.59–9.84) <.001
Insomnia
 No 1
 Yes 3.65 (3.58–3.72) <.001
Musculoskeletal pain
 No 1
 Yes 1.63 (1.61–1.65) <.001
Alcohol-use disorder
 No 1
 Yes 2.30 (2.21–2.39) <.001
Epilepsy
 No 1
 Yes 1.81 (1.72–1.90) <.001
Any associated diagnosis
d
 No N/A N/A
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Characteristic AOR (95% CI)
a P
 Yes 1.15 (1.12–1.19) <.001
AOR indicates adjusted odds ratio; CCI, Charlson Comorbidity Index; N/A, not applicable.
a
AORs are derived from a model that includes all variables listed in this table.
b
Race/ethnicity data were self-reported by patients and recoded administratively into predefined categories.
c
AOR corresponds to a 1-point increment in the CCI score.
d
Includes presence of diagnostic codes for an anxiety disorder, insomnia, musculoskeletal pain, or an alcohol-use disorder. This summary variable 
was excluded from multivariate models because of collinearity with individual diagnostic codes.
e
Patients were asked to estimate alcohol use within the past 90 days. Unhealthy alcohol use was defined as more than 7 drinks per week for all 
women and men older than 65 years or more than 14 drinks per week for men 65 years or younger. See eAppendix Methods for additional 
information.
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